Pharma BD Deal Intelligence
Shire plc / Pervasis Therapeutics, Inc.
2012 · Asset Purchase · $200M · Complete
Announcement Sentiment
83
Strongly positive
Shire acquired substantially all Pervasis Therapeutics assets for an undisclosed upfront plus milestone payments totaling up to ~$200M. Added Phase 2 Vascugel cell-based vascular access therapy to Shire's regenerative medicine business (alongside Dermagraft from 2011 Advanced BioHealing deal).
Did it work? Outcome assessment Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
Announced Apr 09, 2012 Closed Apr 09, 2012 Deal value $200M Deal type Asset Purchase Therapeutic area Hemodialysis vascular access failure (end-stage renal disease) Indications Hemodialysis vascular access failure (end-stage renal disease) Key assets Vascugel (SRM003) - cell-based vascular implant Mechanism Allogeneic endothelial cell-based regenerative therapy
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About